Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the diagnosis, management, and hormone treatment of transsexual individuals, and examines the risks and effects of cross-sex hormone therapy without presenting new clinical results.

This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.

This article provides a comprehensive overview of polycystic ovary syndrome, its diagnosis, complications, and symptom-focused management options, but does not present new clinical findings.

This study reports that diffuse alopecia of the scalp developed in some women during or after using oral contraceptive drugs, suggesting a potential link between the medication and hair loss.

Different drugs are used to manage breeding, prevent or end pregnancy, and treat reproductive issues in dogs and cats.

This review discusses the effects and selection criteria of different progestogens in various treatments but reports no direct clinical comparisons of their metabolic effects.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

Some drugs can cause hair loss, and stopping these drugs often leads to hair regrowth.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

Some drugs can cause hair loss or growth, but hair usually returns to normal after stopping the drug.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.

This study found that finasteride was associated with more reproductive adverse effects, including sexual dysfunction in men and fetal harm in women, compared to minoxidil in reported alopecia cases.

This article reviews new drug therapies for endocrine disorders, discussing specific treatments such as trilostane for hyperadrenocorticism and various insulins for diabetes mellitus, but it reports no new clinical findings.

This review discusses potential drug interactions between herbal medicines and oral contraceptives, reporting no new research results but highlighting the risk these interactions pose to contraceptive effectiveness.

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.

This study identified significant trends in interest around selective androgen receptor modulators, with increasing attention contrasting stagnant or declining interest in post-cycle therapies and anabolic steroids, and calls for clinicians to use social and prescription data to adjust treatment protocols accordingly.

This study found that while ethinyl oestradiol and cyproterone acetate effectively treated hirsutism in 90% of patients, 80% experienced relapse within six months after stopping treatment, suggesting long-term use is necessary.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This case report suggests that the progestogen-only pill may cause false-positive aldosterone/renin ratio results in primary hyperaldosteronism screening, indicating it should be omitted before testing.

This review discusses skin diseases related to contraceptive use, reporting potential issues with oral contraceptives and infrequent reactions to mechanical or barrier methods without new clinical findings.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This article outlines a practical method for diagnosing and managing feline symmetrical alopecia but presents no new empirical findings.

This review discusses the 2011 publications on the side effects of sex hormones and related compounds, without reporting new clinical results.

This article reviews the discovery and various physiological effects of cyproterone acetate, reporting its established indications for several androgen-driven conditions but providing no new clinical data.

This review discusses idiopathic hirsutism and suggests that combination treatment, including androgen suppression and cosmetic methods, is most effective, but notes that its pathogenesis remains unclear.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review explores the use of topical and transdermal delivery for drugs and cosmetics, highlighting the benefits of avoiding side effects and rapid metabolism, with a focus on nanoparticulate formulations and techniques for studying skin penetration.

This review discusses potential treatments for androgen excess in polycystic ovary syndrome and reports no new findings, emphasizing the importance of individualized antiandrogenic management to minimize side effects.

This review explores the evaluation and treatment of hirsutism, emphasizing a systematic approach to uncovering its causes and recommending combination therapies for effective management, but presents no new results.